Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Gorilla's H1 revenue nearly doubled and FY2026 guidance was raised to at least $200M, but a sharp gross-margin decline, widening IFRS losses, and convertible-debt concerns have bulls and bears locked in a bitter post-earnings war over whether growth or profitability is the real story.

NVDA's announcement of a strategic investment in Blackstone-backed Lancium to expand AI data center capacity is the key driver, feeding into the AI infrastructure narrative. Retail sentiment is anxious and split ahead of the earnings report, with many pointing to the stock's seven-day losing streak and pre-earnings selloff as either a bearish omen or a buying opportunity, while others cite the SpaceXAI Vera CPU deployment and Groq 3 LPX production news as bullish catalysts.

Chips are getting dumped hard as the AI trade unwinds, with NVDA's looming earnings serving as the decisive catalyst for whether $SMH holds key support near $540 or breaks down further. The community is split bears point to broken charts, heavy put accumulation, and a rotation into software ($IGV), while bulls see a potential bear trap and squeeze setup into the print.

Community chatter centers on the post-offering reverse split and the massive overhang of newly issued shares and warrants, fueling a mix of speculative 'fly back to $250' calls and stark dilution warnings. Traders are dissecting the terms of the $80M private placement and the six-month lockup, while comparisons to the stock's notorious 2023 parabolic run keep both bulls and skeptics highly engaged.

Community sentiment is bullish, with holders accumulating and rallying for a short squeeze at key resistance. Anticipation around the Clarity Act and potential exchange listings, along with daily trending status, keeps the token in the spotlight.

White House psychedelic push and FDA overhaul have the sector buzzing, while the Lilly-Atai deal is fueling buyout speculation for CMPS as its NDA nears.

Arbutus Biopharma is trending as traders react to its planned $230M Dutch-auction buyback funded by the Moderna LNP settlement, with the community focused on the potential to retire ~20% of shares and the ongoing Pfizer/BioNTech litigation as the next catalyst. Heavy volume with little price movement has fueled speculation of accumulation and a possible squeeze.

The 4CHAN community is rallying around the token's identity as the 'bitcoin of memecoins,' touting its 13 zeros, three-year consolidation, and unique tokenomics (burned supply, blacklisted wallets) as the ultimate scarcity play. Conversations focus on memetic warfare, the 'supernova' breakout, and the belief that dropping zeros will mint millionaires, with holders urging others to stack quadrillions before a potential exchange listing.

MA ripped to fresh all-time highs, with the community pointing to bullish momentum, a strong read-through from Visa's earnings, and President Trump's disclosed purchases of both payment giants as key catalysts. The prevailing sentiment is that MA is finally breaking out after a prolonged consolidation, outshining the laggard narrative and fueling expectations for further upside.

A massive China recall over door-handle safety is being framed as a routine software fix by bulls, but it's fueling bearish sentiment as the stock pulls back sharply. The community is hyper-focused on the upcoming Cybercab launch and Nevada robotaxi approvals as the key catalysts, with bulls treating the dip as a buying opportunity ahead of a potential 'sell the news' event.